SciSparc shares rise 10.53% premarket after NeuroThera unit granted U.S. patent for cannabinoid-antibiotic platform targeting MRSA.

SciSparc surged 10.53% in premarket trading following the announcement that its subsidiary, NeuroThera Labs, was granted a U.S. patent for a proprietary cannabinoid-antibiotic combination targeting antimicrobial resistance, including MRSA. The patent, which adds to prior grants in the U.S. and Europe, strengthens intellectual property protection for NeuroThera’s platform, which uses cannabinoids like THC and CBD to enhance the efficacy of existing antibiotics. The development addresses a critical market need, as MRSA alone caused 130,000 global deaths in 2021, with the antibiotics market projected to reach $58 billion by 2026. SciSparc’s 75% controlling stake in NeuroThera positions it to benefit from the commercialization of this technology, which leverages preclinical data showing improved antimicrobial activity and safety profiles.